OOIR: Observatory of International Research

Papers

(The median citation count of Alzheimers & Dementia is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)

Article	Citations
Issue Information	2238
Cis p‐tau underlies vascular contribution to cognitive impairment and dementia, but is effectively targeted by immunotherapy	1732
	999
RBFOX1 is regulated by the adenosine 2a receptor and is ubiquitinated in tau tangles in Alzheimer’s disease	912
	558
Melatonin, metformin, and ranolazine equally improved cognitive function in rats with doxorubicin‐induced chemobrain	394
High‐fat diet reduced dendritic spine density, but it did not affect cognitive function in spontaneous diabetic torii rats	298
Prevalence of neuropsychiatric conditions and cognitive impairment in two parallel, aging study cohorts from rural and urban India	293
	265
Reframing motherhood in dementia research: A call for action	185
	182
Cerebrospinal fluid biomarkers in the Longitudinal Early‐onset Alzheimer's Disease Study	174
Putting participants and study partners FIRST when clinical trials end early	171
Entorhinal vessel density correlates with phosphorylated tau and TDP‐43 pathology	168
Potential role of blood pressure variability and plasma neurofilament light in the mechanism of comorbidity between Alzheimer's disease and cerebral small vessel disease	167
Plasma amyloid beta predicts conversion to dementia in subjects with mild cognitive impairment: The BALTAZAR study	163
Dementias Platform UK: Bringing genetics into life	151
Mendelian randomization highlights causal association between genetically increased C‐reactive protein levels and reduced Alzheimer's disease risk	150
Subjective cognitive decline across ethnoracial groups in the A4 study	145
A brain atlas of astrocyte transcriptomics unveils complex states and responses to Alzheimer’s disease neuropathology	144
Amyloid‐Beta PET Synthesis from Structural MRI: A Potential Alternative Method for Alzheimer’s Disease Screening	135
Weight loss and risk of dementia in individuals with versus without obesity	133
Issue Information	127
Combining high‐resolution ex vivo MRI and histopathology to identify medial temporal lobe atrophy patterns specific to tau pathology in Alzheimer’s Disease	125
2021 Annual Report of Japanese Brain Bank Network for Neuroscience Research	121

Ethnic Disparities in Clinical Presentation of Patients with Early‐Onset Alzheimer’s Disease	121
The relationship between cortical grey to white matter signal contrast (GWC) and tau pathology in atypical AD	120
Characterising the covariance pattern between lifestyle factors and structural brain measures: a multivariable study of two cohorts of older adults	111
Exploring Social Engagement in a Virtual Participatory Culinary Nutrition Education Intervention for Dementia Prevention	105
In Vivo Head‐To‐Head Comparison of [¹⁸F]GTP1 and [¹⁸F]PI2620 in Alzheimer’s Disease	104
Prevalence of Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) in the United States Medicare population	100
Plasma biomarkers, memory impairment, and imaging measures of Alzheimer’s disease in American Indians	98
Reducing Risk of ADRDs: Innovative Framework to Inform Behavior Change	96
Plasma phosphorylated tau 181 and modifiable risk factors for dementia in a large scale cohort of Australian older adults	93
Characterizing amyloid positive individuals with normal tau PET levels five years later: An ADNI study	86
Brain‐Penetrable Antibody Probes for in vivo Tau Imaging	85
Is QEEG an effective biomarker in predicting cognitive decline?	84
The association of gait velocity and cognitive performance in a sample of older Chinese Americans: A pilot study	84
Racial disparities in Alzheimer’s Disease (AD): Correlating a novel neuropsychological screening test to established AD fluid and imaging biomarkers in African Americans and Caucasians	78
Prediction of amyloid‐beta accumulating normal cognitive elderly	77
Prevalence and pathological correlates of unawareness of memory impairment in non‐demented individuals with autosomal dominant Alzheimer’s disease: an item‐level investigation of the Memory Complaints	76
Understanding differences in antidepressant use patterns among african american and white volunteers with dementia	76
Quantitative amyloid PET in the AMYPAD diagnostic and patient management study	75
Ancestry‐Specific eQTL Associations in AA/NHW Alzheimer Disease Cohorts	74
A systematic evaluation of hippocampal GABA levels in transgenic mouse models of amyloid and tau	72
The impact of the COVID‐19 pandemic on cognitive health	71
Technical performance and biotemporal stability evaluation of Olink proximity extension assay for blood‐based biomarker discovery	70
The troubles and needs of family caregivers of older adults with moderate to severe dementia	68
Depression in Alzheimer’s disease hospitalized patients: A descriptive analysis of a nationwide database	68
Transgender adults report greater cognitive and related functional challenges: Findings from the 2015‐2019 Behavioral Risk Factor Surveillance System	67
CSF amyloid, tau, and neurodegeneration biomarkers are associated with longitudinal cognitive decline in preclinical AD	66
Hyperintensity on Diffusion‐Weighted MRI and Clinical Correlations in Probable Creutzfeldt‐Jakob Disease	66
Increased regional brain inflammation predicts longitudinal brain atrophy in individuals in the Alzheimer’s disease continuum	65
Associations of sleep disturbances with cognitive function and plasma Alzheimer’s biomarkers in Chinese rural‐dwelling older adults: A population‐based study	64
Investigation of sex differences in mutation carriers of the Dominantly Inherited Alzheimer Network	63
Rural/Urban Disparities in PQIs Among Patients with ADRD – Evidence of Hospital‐based HIT and Enabling Services	63
Association of Epigenetic Aging with Cognitive Aging in Diverse Hispanics/Latinos	62
From identification to implementation: state of the art in biomarkers for immune function in CSF and blood	62
Testamentary Capacity Assessment Tool (TCAT): An update report	62
Impaired retinal capillary function in patients with clinical Alzheimer’s disease	61
Explainable AI and its instantiation in Computational Pathology for a better understanding of Alzheimer’s disease	61
Association of anticholinergic medication and AD biomarkers among cognitively normal late middle‐age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP)	61
A comprehensive literature search of digital health technology use in dementia: Digital tools to support dementia caregivers	60
Association of air quality reduction with incident dementia: Effects of natural course and hypothetical air pollutant interventions using g‐computation	59
Cognitive impairment prevention and healthy aging. A multidisciplinary team work	59
Theta‐Gamma Phase‐Amplitude Coupling Deficit in Streptozotocin AD Rat Model	58
Systemic and central nervous system metabolome changes associated with Ginkgo biloba treatment in non‐demented subjects	58
Generative Adversarial Network‐Enhanced Ultra‐low‐dose [18F]‐PI‐2620 Tau PET/MR Imaging	57
Language, cognitive and neuroimaging determinants of Primary Progressive Aphasia in Hebrew Speakers, a case series	57
Persistent pain is associated with lower locus coeruleus integrity in older adults	57
Networking analysis for neuroimaging and genetic markers in Alzheimer's disease	57
CaMKIIα signaling is required for the neuroprotective effects of Dl‐3‐n‐butylphthalide in Alzheimer’s disease	56
Decorin is an early CSF biomarker of Alzheimer’s Aβ amyloidosis	55
LANGaware: Introducing the right solution for the early detection of neurodegenerative and psychiatric diseases	55
The association between diabetes and Alzheimer’s disease pathophysiology	54

Improved functional connectivity after a 6‐month ketogenic supplementation in mild cognitive impairment	54
Are there trends towards compression of morbidity for dementia? Evidences from four international population‐based cohorts	53
Unsupervised Learning‐based Drug Repositioning for Alzheimer’s Disease Targeting Brain Cell Type Specific Genetic Subtypes	51
Interaction between polymorphisms in MBP and EIF2B5 genes is significantly associated with Alzheimer’s disease	51
Associations between imaging biomarkers and sleep quality in the U.S. POINTER study baseline cohort	51
Clinical validation of the Eli Lilly SPX P‐tau217 blood‐based immunoassay as a laboratory‐developed test (LDT)	51
The influence of amyloid on tau deposition in clinically obese participants	50
Assessing attitudes and beliefs of dementia risk and prevention in middle‐aged adults	50
Subjective Social Status, Brain Health, and Cognitive Reserve Across Race/Ethnicity and Sex/Gender	50
Influence of tau on non‐traditional memory scores in early‐onset Alzheimer’s disease	49
A machine learning approach to predict amyloid and tau positivity using clinical features	49
Genetic Screening of Frontotemporal Dementia Patients from a Memory Clinic in Argentina	49
A cross‐sectional analysis of Alzheimer’s disease plasma biomarkers and gait variables in cognitively normal older adults	49
Decline in cognitive trajectories in the neuropathological spectrum of Lewy Body disease	48
Issue Information	48
Elderly Role Performance Occupational Therapy	48
A Placebo‐Controlled Phase I Study in Healthy Subjects Assessing NVG‐291, which Targets CNS Receptor Protein Tyrosine Phosphatase Sigma (PTPσ)	48
Prevalence of Dementia among Malawian adults with HIV and without HIV: A Medical Record Review	48
Improving Early Detection of White Matter Degeneration in Aging and Dementia along the AD continuum	47
Experiences of People Living with Dementia and their Care Partners in Participating in Outdoor Activities	47
Comparison of remote and in‐person digital speech‐based measures of cognition	47
WVE‐005, a stereopure antisense oligonucleotide for MAPT silencing in tauopathies	47
Bibliographic Analysis of Aging Anxiety and Lifestyle	47
Outreach and recruitment of African Americans for Alzheimer’s disease studies during the COVID‐19 pandemic	46
Cardiorespiratory fitness is an important marker of cognitive performance in older Latin Americans	46
Visual memory test equal to commonly used verbal memory test in predicting tau in the medial temporal lobe	46
A 10‐minute Digitally Administered and Scored Neuropsychological Protocol Assessing Executive Control and Episodic Memory	46
Plasma GFAP:NfL discriminates FTLD‐tau from FTLD‐TDP	46
Cerebellar‐cortical functional connectivity is associated with Alzheimer’s disease pathology and cerebellar atrophy	45
Recognizing human functional patterns in IADLs through hand detection and artificial intelligence	45
Usability experience of remote sleep monitoring in patients with neurodegenerative diseases	45
Microvascular Morphology MR Imaging Using Relaxation Rate Change with Gadolinium‐Based Contrast Agent in Patients with Alzheimer’s Disease	45
The effect of virtual reality and physical exercise training on cognitive function in older adults with mild cognitive impairment	45
Cognitive correlations with amyloid, tau and neurodegeneration PET across the Alzheimer’s disease age spectrum	45
Characteristics of peripheral immune system in a novel App^NL‐G‐F knock‐in mouse model of Alzheimer’s disease	44
Hypogyrification in midlife women with surgical menopause, a population at risk for late life Alzheimer’s	44
Cerebral perfusion and amyloidosis in the oldest‐old	44
Association between ¹⁸F – FDG uptake and global cognitive performance in individuals at risk of dementia	44
Dementia‐inclusive radio series ‘Talkin’ About Neurodegeneration'—A look under the dementia umbrella and a follow‐on series to award‐winning ‘Voyage Around My Brain’ on NearFM	44
What attributes have been included in discrete choice experiments related to health technologies used in the early detection, diagnosis and treatment of neurodegenerative conditions? A systematic lite	43
CASBA neurological assessment: Noninvasive EEG biomarkers classify amyloid‐PET, clinical diagnosis, cognitive dementia rating, and FCSRT free recall scores in patients with cognitive decline	43
Assessment of apathy‐like behaviour in transgenic mouse models of neurodegenerative diseases	43
Inflammation and working memory performance in everyday life: Gender differences among older adults with and without cognitive impairment	43
A Study of Factors Influencing Quality of Life among Community Dwelling Elderly in Korean Urban Community	43
Exploring Inflammasome/Cytokine/Insulin cascade as converging landscape for AD, Schizophrenia(SCHIZO), and COVID‐19 syndrome: synthesis of evidence and Post‐hoc analysis of Ginsans‐115 RCT in treatmen	42
TMS‐based measures of cortical excitability are related to distributed atrophy in early Alzheimer’s disease	42
High Social Deprivation as a Risk Factor for Dementia: Findings from the longitudinal SHARE study of older Europeans	42
Exploring the role of brain DNA methylomic signatures on gene expression dynamics of frontotemporal lobar degeneration	41
Longitudinal white matter hyperintensities in Down’s syndrome	41
Single‐nucleus RNAseq‐derived pseudo‐temporal modeling of neurodegeneration in astrocytes of older brains	41
PAS‐MCI: Design and rationale for a randomized controlled trial to enhance prefrontal cortical plasticity and working memory in individuals with amnestic mild cognitive impairment	41
Impact of left censoring on longitudinal analyses of dementia using electronic health record data	41
Astrocyte reactivity is associated with synaptic dysfunction across the aging and Alzheimer’s disease spectrum, whereas microglial reactivity is specifically associated with synaptic dysfunction relat	41
Developing a preference‐based quality of life for people living with dementia in Vietnam	40
Interneuron hyperexcitability in an APP/PS1 mouse model of Alzheimer’s disease	40
Bridging the Gap: The Global CEOi Collaborative Workgroup for Adoption of Alzheimer’s disease Blood‐Based Biomarkers in Clinical Practice	40
Recruitment data of the HAPPCAP‐AD (Human‐APPlication Combined Approach for Prevention of Alzheimer’s Disease): a feasibility study	40
Behavioral reaction to amyloid beta status disclosure	40
Transient CSF1R Inhibition in the Early Stage of AD Retains Homeostatic Microglia with Reduced Inflammasomes and Increased autophagy in the 5XFAD Model	40
Seizures exacerbate tau spread in the 5XFAD mouse model	40
A Rule‐Based Framework to Identify Severity of Dementia from Unstructured Electronic Health Record Data	40
Transition in the cognitive continuum from normal cognition to dementia: the interplay of lifelong cognitive reserve with brain aging and genetic predisposition	39
Comparison of histological delineation of the entorhinal, perirhinal, ectorhinal, and parahippocampal cortices by different neuroanatomy laboratories	39
White matter hyperintensities: A long‐term consequence of repetitive head impacts?	39
Antagonistic Amyloid‐β and tau interactions with T1‐weighted/T2‐weighted magnetic resonance ratio in Alzheimer’s disesase continuum	39
Assessment of ccf‐Mitochondrial DNA Damage in Cognitive Impairment via NGS: Health Disparities in Mexican Americans	39
Validated, unified theory of Alzheimer Disease illuminates two essential research questions	39
Advanced measures of cortical microstructural change and associations with cognitive and blood‐based biomarkers in autosomal dominant Alzheimer’s disease	39
Mechanisms Mediating the Anti‐inflammatory Effects of Eicosapentaenoic Acid in the APPswePS1dE9 Alzheimer's Mouse Model	39
Loss of apolipoprotein E exacerbates microglial and astrocyte reactivity to sustained systemic glucocerebrosidase inhibition	39
Baseline Frailty and Domain‐specific Cognitive Declines in Healthy and MCI Older Adults	38
Longitudinal associations between racial discrimination and brain aging among black older adults	38
Clinically relevant monitoring of long‐term night‐time behaviour and physiology from the homes of people living with dementia	38
Ameliorative effects of Aqueous Fruit Pulp Extracts of Adansonia digitata on the Hippocampus of Aluminium Chloride‐treated Adult Wistar Rats	38
Modifiable dementia risk factor associations with AT(N) biomarkers: Findings from the European Prevention of Alzheimer’s Dementia study	38
Smartphone ownership and usage in Chinese‐ and English‐speaking older adults	37
Fish intake and MRI burden of cerebrovascular disease in older adults	37
The use of the Cognitive Change Questionnaire by community health workers as dementia screening method	37
Combination of baicalein and trans‐chalcone synergistically reduces amyloid beta and its toxicity in yeast	37
The effect of prolonged lockdown due to COVID‐19 on demented patients of different stages and on their caregivers	37

Automating the verbal paired associates test to assess memory remotely and at scale	36
Re‐evaluation of the genetic role of a rare APOE variant (L28P; APOE^4Pittsburgh*) in late‐onset Alzheimer disease	36
Memory decline is not normal, healthy brain aging	36
Circulating extracellular vesicles of neurovascular origin are elevated in women with severe preeclampsia years after their affected pregnancies	36
Associations of hippocampal cholinergic receptor binding and subcortical cerebrovascular disease with whole brain volume in cognitive aging and AD	36
Racial‐ethnic differences in baseline and longitudinal change in neuropsychological test scores in the NACC Uniform Data Set 3.0	36
Autophagy and lysosomal defects in cells expressing disease‐associated tau	36
Tracing individual trajectory of longitudinal tau spreading in deep latent space	36
Premature aging in co‐occurring Alcohol Use Disorder and Post‐Traumatic Stress Disorder from a functional connectome perspective	36
β‐secretase inhibition prevents structural spine plasticity deficits in AppNL‐G‐F mice	36
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology	35
Heart failure associations with cerebral structure: combined analysis from the Multi‐Ethnic Study of Atherosclerosis (MESA) and the SECRET‐II trial of heart failure with preserved ejection fraction	35
Policy recommendations from the perspective of health professionals who work with people with dementia in public tertiary hospitals in China	35
AD‐Associated Variants Directly Impair Surface Interactions Between the Hydrophobic Site of TREM2 and the Hinge Region of ApoE	35
Concordance and diagnostic accuracy between Innotest and two fully automated platforms: Elecsys and Lumipulse	35
The dementia policies in Australia relating to the COVID‐19 pandemic	35
Cortical microstructure is associated with tau burden and predicts cognitive decline and clinical progression in healthy older adults	35
Statistical innovations in the API ADAD Colombia trial: a randomized, double‐blind, placebo‐controlled, parallel‐group study in cognitively unimpaired PSEN1 E280A mutation carriers evaluating efficacy	35
Assessing sex differences between mid‐life cardiovascular conditions or risk factors and mid‐life cognition decline	34
Sex differences in functional network topological measures in the APP‐PS1 mouse model of amyloidosis	34
Trajectories of self‐rated concerns in individuals developing cognitive decline	34
Neuropathological features of antemortem atrophy‐based subtypes of Alzheimer’s disease	34
Neuropathology of a patient with AD treated with low doses of verubecestat	34
Impairment of auditory integration in subjective cognitive decline, amnestic mild cognitive impairment, and Alzheimer’s disease	34
Tau368 in cerebrospinal fluid is associated with severity of tau pathology load in the Alzheimer’s continuum	34
Multi‐center study reveals impairment of cortical tissue oxygenation during rising blood CO2 tension in MCI and AD patients	33
Spatiotemporal transcriptomic characterization of an amyloid mouse model of Alzheimer’s disease	33
COVID‐19 Infection and Dementia: Analyses of time‐varying risk, subtypes, and subpopulations from the UK Biobank	33
The chauffeur who banged cars happily: an interesting case of rapidly progressive strategic infarct dementia	33
Despite heightened risk of cognitive decline, no evidence of local atrophy in people with subjective cognitive decline compared to normal controls in ADNI	33
Human postmortem studies as a driver of biomarker development	32
Development of an artificial intelligence approach that employs genomic and brain imaging features to improve the diagnosis of Alzheimer’s Disease (AD)	32
Tolerability and Likeability of a Cognitive Training Program in an Outpatient Memory Care Clinic	32
Who is at risk of dementia? Trajectories of cognitive decline from mild cognitive impairment to dementia and the factors which mediate this decline	32
Preventing cognitive decline using portable, non‐invasive sleep enhancement.	32
Biomarker driven enrichment strategies for tau pathology in AD clinical trials	32
Measuring synaptic loss in early AD stages: Trajectories of SNAP25 and SYT1 using serial CSF sampling	32
Comparing associations of Alzheimer’s disease plasma biomarkers with remote self‐administered cognitive measures versus in‐person neuropsychological tests	32
Association of life‐course traumatic brain injury with the risk of dementia: a nationwide twin study	32
Validation of Mitochondria‐Targeted AD Therapeutics in Human Neuronal Cells	32
Prevalence, incidence and associations of dementia with cardiovascular risk factors in the Latin American and Caribbean population. A population‐based cohort study of 10/66 Dementia Research Group	32
On the role of neuropsychiatric symptoms as markers for Alzheimer´s disease in an era of disease modifying treatments	32
PDE5 inhibitors against synaptic and cognitive impairment in Alzheimer’s disease and related dementia	32
Meaning from tragedy: exploring attitudes toward dementia patient participation in research	31
A 5‐hydroxymethylation‐based clock derived from cell‐free DNA in blood reveals accelerated epigenetic aging in patients with Alzheimer’s disease	31
Relationship between amyloid and tau levels and its impact on tau spreading	31
Cross‐cultural properties of the Cross‐cultural Dementia Screening test and the European Cross‐Cultural Neuropsychological Test Battery	31
Incorporating clinical trial outcomes in health economic evaluations of disease‐modifying therapies for AD	31
Anti‐ulcer drug teprenone clinical trial	31
Determination of molecular chaperone levels in cerebrospinal fluids of Alzheimer’s patients	31
Applications of PRESS‐MRS, MEGA‐PRESS, and pCASL to evaluate treatment effect of Kami Guibi‐tang on amnestic MCI	31
Using an entorhinal cortex‐based virtual reality navigation task to differentiate between individuals with and without subjective cognitive decline	30
Feasibility of the occupational therapy protocol TAP (Tailored Activity Program) for the management of behaviors in a dementia hospital unit: Preliminary results from a pilot study	30
MRI‐guided Clustering of Alzheimer’s Disease patients: A post‐hoc analysis of Phase 3 Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease	30
Iron intake, brain iron, and Alzheimer’s disease among community‐dwelling older adults	30
Emergence of visual artistic creativity in frontotemporal dementia	30
Myeloid Differentiation Factor 2 Inhibition Protects Against Doxorubicin‐induced Microglial Activation and Senescence	30
CSF tau phosphorylation at sites 217 and 181 are associated with preclinical and biphasic alterations in resting‐state functional connectivity in Autosomal Dominant AD	30
Innovative Methods to Gather, Understand, And Incorporate Diverse Lived Experiences Into Dementia Research	30
In vitro activity of polyphenol‐rich extract of sorghum relevant to treatment of Alzheimer’s disease	30
Association Between Neuropsychiatric Symptoms and Blood‐Based Autoantibody Biomarkers	30
Identifying individuals with non‐AD co‐pathologies: A precision medicine approach to clinical trials in sporadic AD	30
Risk knowledge and risk perception of MCI patients and their caregivers in predictive diagnosis of AD: Findings from the PreDADQoL study	30
Clinical profile of primary progressive Aphasia in Peru: Case series from a Neurological care center	30
Characterizing progressive speech changes in prodromal‐to‐mild Alzheimer’s disease using natural language processing	29
CSF Biomarkers and [¹⁸F]flutemetamol PET‐Derived Centiloids in Patients with SCD or MCI	29
Cognitive health risks posed by social isolation and loneliness in older Korean Americans	29
Predicting Transitions from Mild Cognitive Impairment to Dementia within 5‐years	29
PENSA study for the prevention of cognitive decline in APOE‐ɛ4 carriers with subjective cognitive decline: Description of baseline demographic and neuropsychological data of the study population	29
The heterogeneity of subjective cognitive decline: A data‐driven approach on a population‐based sample	29
Neuroinflammatory biomarkers in neurodegenerative disease: Insights from the ONDRI Cohort	28
Amyloid‐β Pathology Exacerbates Aging‐Induced Dysregulation of C1q Expression in Cortical Neurons	28
The Effect of COVID‐19 Lockdown on Dementia Caregivers in the U.S.	28
Functional connectivity measurements in APP/PS‐1 mice revealed hypo‐connectivity with transient hyper‐connectivity	28
Impact of learning amyloid PET results on test‐related distress and concern about dementia in a cognitively unimpaired observational cohort	28
Relationships between cerebral tau and glucose metabolism in cognitively normal older adults	28
Characterization of behavioral changes, MRI brain volumetry and brain metabolic profile of 5xFAD mouse model of Alzheimer’s disease	28
Baseline and Six‐Month Actigraphy and Sleep‐monitoring Devices Help Differentiate Between Alzheimer’s Disease and Dementia with Lewy Bodies	28
Speed of cognitive decline in biomarker stratified SCD subgroups	28
Tau‐PET imaging with ¹⁸F‐PI‐2620 reveals lateralized distribution of tau pathology in critical language regions in patients with early onset of Alzheimer’s Disease and patients with primary	28
The Role of Cerebrospinal Fluid Flow in the Subarachnoid Space in Beta‐Amyloid Clearance	28
Machine learning algorithm selects transcripts in blood to distinguish Alzheimer’s disease and other neurodegenerative diseases	27
Positive association of Cerebral Amyloid Angiopathy (CAA) with R2 Relaxation rate: A study of ex‐vivo MRI and pathology	27
Exploring the basis of phenotypic diversity in Alzheimer’s disease	27
Resistance and resilience to Alzheimer’s disease pathology associated with lower severity of other neuropathologic diseases	27
Methods in Prioritizing Pathways and Targets from Expression Data	27
Differential Effects of Anticholinergic Medications in a Human Neuronal Model of AD	27
The Aging Brain Clinic (ABC): An innovative model for managing patients with mild cognitive impairment	27
Comparison of Vascular Health in Super‐Agers and Cognitively Normal Adults 80 Years and Older	27
Decline in everyday functioning in relation to cerebral tau burden across the clinical spectrum of Alzheimer’s disease	27
Multimodal MRI and tau PET findings from the Autosomal Dominant Alzheimer’s disease cohort caused by the A431E PSEN1 Jalisco mutation	27
Reproductive health data and its relationship to baseline brain imaging and cognitive measurements in cognitively unimpaired female PSEN1 E280A mutation carriers and non‐carriers from the API ADAD Tri	26
Associations between CSF proteins and medial temporal lobe atrophy across the AD continuum	26
EEG microstates as a “real time” feedback for rTMS treatment efficacy in MCI subjects	26
Characterization of a mouse model as a predictive tool for human Post‐Acute Sequelae of Covid‐19	26